BAKX Therapeutics to shut down after ‘scientific challenges’ and financing doldrums
BAKX Therapeutics will shut down by Aug. 1, ending a “Thelma and Louise” approach to cancer small molecules after scientific, financing and timeline challenges upended …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.